Several studies presented last month at the European Congress on Osteoporosis in Berlin, Germany, offered good news for the prevention of hip and spinal fractures in postmenopausal women and those with osteoporosis.
New results from a second phase of the US-based Fracture Intervention Trial that included 4432 women with thinning bones showed that the drug alendronate can reduce the risk of hip fractures by 56% in women who have never suffered a spinal fracture. The drug also was shown to reduce the risk of an initial spinal fracture by 49%.
Results from another US-based randomized controlled study of 7705 postmenopausal women showed that the selective estrogen receptor modulator raloxifene hydrochloride can reduce the risk of a first spinal fracture by 52%. The drug reduced by 38% the risk of a subsequent spinal fracture in women who had already had one.
Worldwide, more than 200 million women have osteoporosis, . . . [Full Text of this Article]
